← Back
NeuroTrials.ai
Neurology Clinical Trial Database

OPERA 9-Year

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension

Year of Publication: 2025

Authors: João J. Cerqueira, Achim Berthele, Bruce A.C. Cree, ..., and Eva K. Havrdová

Journal: Neurology

Citation: Neurology 2025;104:e210142


Clinical Question

To assess the long-term (9-year) efficacy and safety profile of ocrelizumab as a first-line therapy in a subgroup of treatment-naive patients with early-stage relapsing multiple sclerosis (RMS) from the OPERA I/II trials.

Bottom Line

Early and continuous treatment with ocrelizumab in treatment-naive patients with early RMS provides long-term benefits in controlling disease activity and preventing disability progression over 9 years. The benefits achieved by starting on ocrelizumab early were maintained long-term, and the disability and brain volume loss accrued by patients starting on interferon were not recovered after switching to ocrelizumab.

Major Points

  • This is a post hoc exploratory analysis of a subgroup of 757 treatment-naive patients with early-stage RMS from the OPERA I/II trials and their open-label extension (OLE).
  • Patients were initially randomized to ocrelizumab (OCR-OCR group) or interferon β-1a (IFN-OCR group) for a 96-week double-blind period (DBP), after which all patients received ocrelizumab in the OLE for a total follow-up of 9 years.
  • The higher rate of achieving No Evidence of Disease Activity (NEDA-3) status with ocrelizumab during the DBP (72.5% vs 43.8% with interferon) was maintained throughout the 7-year OLE (48.2% vs 25.7%).
  • Over 9 years, 78.7% of patients who started on and continued ocrelizumab remained free of 24-week confirmed disability progression (CDP).
  • Brain volume loss that occurred during the initial 2 years of interferon treatment was not recovered after switching to ocrelizumab, although the rate of loss became similar between groups after the switch.
  • No new safety signals were observed during the OLE, and the rate of infections remained low and stable over the >9 years of continuous ocrelizumab treatment.

Design

Study Type: Post hoc exploratory analysis of a subgroup from randomized controlled trials with a subsequent open-label extension.

Randomization: 1

Blinding: The initial 96-week period was double-blind and double-dummy. The subsequent extension was open-label.

Follow-up Duration: 9 years

Countries:

Sample Size: 757

Analysis: Post hoc exploratory analysis using pooled data from the OPERA I/II intention-to-treat population who were treatment-naive with an RMS diagnosis ≤2 years. Efficacy endpoints were analyzed using odds ratios, Kaplan-Meier plots, Cox regression, and mixed-effects models.


Inclusion Criteria

  • Subgroup from the original OPERA I/II trials
  • Confirmed diagnosis of relapsing MS (RMS) ≤2 years before inclusion in the study
  • No previous disease-modifying therapy (DMT) treatment

Exclusion Criteria

  • Patients from the original trials who did not meet the subgroup criteria for early RMS or prior DMT use.

Arms

FieldControlOCR-OCR (Early Start)
InterventionSubcutaneous interferon β-1a (44 µg 3x/week) for 96 weeks, then switched to intravenous ocrelizumab (600 mg every 24 weeks) in the open-label extension.Intravenous ocrelizumab (600 mg every 24 weeks) for the entire 9-year study period (96-week double-blind phase and subsequent open-label extension).
Duration9 years9 years

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
This analysis focused on long-term efficacy, primarily No Evidence of Disease Activity (NEDA-3) and 24-week Confirmed Disability Progression (CDP).Primary
NEDA-3 status over the entire 9-year periodSecondary25.7%48.2%Odds Ratio 2.72 (95% CI 1.94-3.82)<0.0001
Time to 24-week CDP over 9 yearsSecondary30% of patients experienced CDP26% of patients experienced CDPHR 0.80 (95% CI 0.59-1.07)0.135
Annualized Relapse Rate (ARR) over 9 yearsSecondary0.090.05Adjusted rate ratio of 0.6270.0036
AEs leading to discontinuation (over 9 years)Adverse9.9%8.3%
Rate of serious infections (per 100 patient-years)Adverse1.28
Rate of malignancies (per 100 patient-years)Adverse0.53

Criticisms

  • This was a post hoc exploratory analysis of a specific subgroup, not a prospectively defined primary analysis.
  • Assessment bias could have been introduced due to the open-label nature of the extension period.
  • Although the 9-year completion rate was high (67%), attrition bias remains a potential limitation.

Funding

F. Hoffmann-La Roche Ltd

Based on: OPERA 9-Year (Neurology, 2025)

Authors: João J. Cerqueira, Achim Berthele, Bruce A.C. Cree, ..., and Eva K. Havrdová

Citation: Neurology 2025;104:e210142

Content summarized and formatted by NeuroTrials.ai.